New hope for duchenne? experimental drug BMN 351 enters human testing
NCT ID NCT06280209
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a drug called BMN 351 in 18 boys aged 4 to 10 with Duchenne muscular dystrophy who have a specific genetic change. The drug is designed to help the body produce a shorter but still useful version of the muscle protein dystrophin. The main goal is to check the drug's safety and how the body processes it, not yet to prove it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BMN 351 (an antisense oligonucleotide designed to skip exon 51 in the dystrophin gene)
What this could lead to
If successful, this could lead to a treatment that helps boys with Duchenne muscular dystrophy produce a shorter but functional version of the dystrophin protein, potentially slowing muscle decline.
What could go wrong
This is an early phase 1/2 trial with only 18 participants, so safety and dosing are still being established. It is not yet known if BMN 351 will meaningfully improve muscle function or quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DUCHENNE MUSCULAR DYSTROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fondazione Serena ETS - Centro Clinico NeMO Milano
Milan, Italy
-
Great Ormond Street Hospital NHS Foundation Trust
London, WC1N 3JH, United Kingdom
-
Hospital Sant Joan de Deu
Barcelona, 08950, Spain
-
Hospital Viamed Santa Angela De la Cruz
Seville, 41013, Spain
-
Leids Universitair Medisch Centrum
Leiden, 2333 ZA, Netherlands
-
UOC Fase I - Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore
Rome, Italy
-
Yeditepe University Kosuyolu Hospital
Istanbul, Turkey (Türkiye)